{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:30:07Z","timestamp":1793446207417,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41401-025-01650-3","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:20:25Z","timestamp":1756711225000},"page":"255-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOCS1 depletion drives osteosarcoma stemness and chemoresistance by suppressing ACTN4 degradation"],"prefix":"10.1038","volume":"47","author":[{"given":"Jin-yan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-fu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-wu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-xin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"1650_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Prim. 2022;8:77.","journal-title":"Nat Rev Dis Prim"},{"key":"1650_CR2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385:2066\u201376.","journal-title":"N Engl J Med"},{"key":"1650_CR3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18:609\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1650_CR4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31:617\u201339.","journal-title":"Cell Stem Cell"},{"key":"1650_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","volume":"12","author":"LV Nguyen","year":"2012","unstructured":"Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133\u201343.","journal-title":"Nat Rev Cancer"},{"key":"1650_CR6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cac2.12138","volume":"41","author":"G Pan","year":"2021","unstructured":"Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 2021;41:199\u2013217.","journal-title":"Cancer Commun"},{"key":"1650_CR7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2016.11.019","volume":"386","author":"HK Brown","year":"2017","unstructured":"Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189\u201395.","journal-title":"Cancer Lett"},{"key":"1650_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.molmed.2017.06.004","volume":"23","author":"YH Lin","year":"2017","unstructured":"Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, et al. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol Med. 2017;23:737\u201355.","journal-title":"Trends Mol Med"},{"key":"1650_CR9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1074-7613(00)00028-5","volume":"13","author":"XP Chen","year":"2000","unstructured":"Chen XP, Losman JA, Rothman P. SOCS proteins, regulators of intracellular signaling. Immunity. 2000;13:287\u201390.","journal-title":"Immunity"},{"key":"1650_CR10","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","volume":"130","author":"DF Calvisi","year":"2006","unstructured":"Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC. Gastroenterology. 2006;130:1117\u201328.","journal-title":"Gastroenterology"},{"key":"1650_CR11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/43206","volume":"387","author":"R Starr","year":"1997","unstructured":"Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917\u201321.","journal-title":"Nature"},{"key":"1650_CR12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2009.09.009","volume":"30","author":"DC Palmer","year":"2009","unstructured":"Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009;30:592\u2013602.","journal-title":"Trends Immunol"},{"key":"1650_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.it.2009.07.001","volume":"30","author":"BJ Baker","year":"2009","unstructured":"Baker BJ, Akhtar LN, Benveniste EN. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 2009;30:392\u2013400.","journal-title":"Trends Immunol"},{"key":"1650_CR14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1073\/pnas.96.5.2071","volume":"96","author":"JG Zhang","year":"1999","unstructured":"Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA. 1999;96:2071\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1650_CR15","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","volume":"83","author":"J Zhuang","year":"2023","unstructured":"Zhuang J, Shen L, Li M, Sun J, Hao J, Li J, et al. Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res. 2023;83:1611\u201327.","journal-title":"Cancer Res"},{"key":"1650_CR16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/gcc.10222","volume":"37","author":"CY Chen","year":"2003","unstructured":"Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:300\u20135.","journal-title":"Genes Chromosomes Cancer"},{"key":"1650_CR17","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood-2002-06-1735","volume":"101","author":"O Galm","year":"2003","unstructured":"Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101:2784\u20138.","journal-title":"Blood"},{"key":"1650_CR18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00535-004-1373-2","volume":"39","author":"K Ohkawa","year":"2004","unstructured":"Ohkawa K. Suppressor of cytokine signaling 1, a newly proposed tumor suppressor gene associated with hepatocellular carcinoma. J Gastroenterol. 2004;39:598\u2013600.","journal-title":"J Gastroenterol"},{"key":"1650_CR19","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1038\/sj.onc.1205537","volume":"21","author":"R Rottapel","year":"2002","unstructured":"Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21:4351\u201362.","journal-title":"Oncogene"},{"key":"1650_CR20","first-page":"4","volume":"28","author":"T Kishimoto","year":"2001","unstructured":"Kishimoto T, Kikutani H. Knocking the SOCS off a tumor suppressor. Nat Genet. 2001;28:4\u20135.","journal-title":"Nat Genet"},{"key":"1650_CR21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.molcel.2009.09.044","volume":"36","author":"V Calabrese","year":"2009","unstructured":"Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, Moores A, et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell. 2009;36:754\u201367.","journal-title":"Mol Cell"},{"key":"1650_CR22","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1038\/onc.2015.485","volume":"35","author":"M Yeganeh","year":"2016","unstructured":"Yeganeh M, Gui Y, Kandhi R, Bobbala D, Tobelaim WS, Saucier C, et al. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1\/WAF1) in the liver. Oncogene. 2016;35:4200\u201311.","journal-title":"Oncogene"},{"key":"1650_CR23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0022-202X.2004.23408.x","volume":"123","author":"Z Li","year":"2004","unstructured":"Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 2004;123:737\u201345.","journal-title":"J Invest Dermatol"},{"key":"1650_CR24","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1158\/0008-5472.CAN-08-1429","volume":"68","author":"FJ Huang","year":"2008","unstructured":"Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, et al. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res. 2008;68:9634\u201342.","journal-title":"Cancer Res"},{"key":"1650_CR25","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s00018-008-8080-8","volume":"65","author":"B Sjoblom","year":"2008","unstructured":"Sjoblom B, Salmazo A, Djinovic-Carugo K. Alpha-actinin structure and regulation. Cell Mol Life Sci. 2008;65:2688\u2013701.","journal-title":"Cell Mol Life Sci"},{"key":"1650_CR26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mds215","volume":"24","author":"A Miyanaga","year":"2013","unstructured":"Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol. 2013;24:84\u201390.","journal-title":"Ann Oncol"},{"key":"1650_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcdb.2017.05.024","volume":"71","author":"DG Thomas","year":"2017","unstructured":"Thomas DG, Robinson DN. The fifth sense: Mechanosensory regulation of alpha-actinin-4 and its relevance for cancer metastasis. Semin Cell Dev Biol. 2017;71:68\u201374.","journal-title":"Semin Cell Dev Biol"},{"key":"1650_CR28","doi-asserted-by":"crossref","unstructured":"Tentler D, Lomert E, Novitskaya K, Barlev NA. Role of ACTN4 in tumorigenesis, metastasis, and EMT. Cells. 2019;8:1427.","DOI":"10.3390\/cells8111427"},{"key":"1650_CR29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2004.10.004","volume":"128","author":"K Honda","year":"2005","unstructured":"Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology. 2005;128:51\u201362.","journal-title":"Gastroenterology"},{"key":"1650_CR30","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1038\/onc.2016.117","volume":"35","author":"HT An","year":"2016","unstructured":"An HT, Yoo S, Ko J. alpha-Actinin-4 induces the epithelial-to-mesenchymal transition and tumorigenesis via regulation of Snail expression and beta-catenin stabilization in cervical cancer. Oncogene. 2016;35:5893\u2013904.","journal-title":"Oncogene"},{"key":"1650_CR31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/modpathol.2008.234","volume":"22","author":"S Yamamoto","year":"2009","unstructured":"Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, et al. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol. 2009;22:499\u2013507.","journal-title":"Mod Pathol"},{"key":"1650_CR32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgz168","volume":"41","author":"J Jung","year":"2020","unstructured":"Jung J, Kim S, An HT, Ko J. alpha-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer. Carcinogenesis. 2020;41:940\u20139.","journal-title":"Carcinogenesis"},{"key":"1650_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-024-01956-4","volume":"9","author":"M Zhu","year":"2024","unstructured":"Zhu M, Huang F, Sun H, Liu K, Chen Z, Yu B, et al. Characterization of ACTN4 as a novel antiviral target against SARS-CoV-2. Signal Transduct Target Ther. 2024;9:243.","journal-title":"Signal Transduct Target Ther"},{"key":"1650_CR34","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1111\/febs.12828","volume":"281","author":"S Sharma","year":"2014","unstructured":"Sharma S, Mayank AK, Nailwal H, Tripathi S, Patel JR, Bowzard JB, et al. Influenza A viral nucleoprotein interacts with cytoskeleton scaffolding protein alpha-actinin-4 for viral replication. FEBS J. 2014;281:2899\u2013914.","journal-title":"FEBS J"},{"key":"1650_CR35","volume":"14","author":"M Cheng","year":"2023","unstructured":"Cheng M, Cao H, Yao P, Guan J, Wu P, Ji H, et al. PHF23 promotes NSCLC proliferation, metastasis, and chemoresistance via stabilization of ACTN4 and activation of the ERK pathway. Cell Death Dis. 2023;14:558.","journal-title":"Cell Death Dis"},{"key":"1650_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0968-0004(02)02085-6","volume":"27","author":"BT Kile","year":"2002","unstructured":"Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci. 2002;27:235\u201341.","journal-title":"Trends Biochem Sci"},{"key":"1650_CR37","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1101\/gad.1252404","volume":"18","author":"T Kamura","year":"2004","unstructured":"Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004;18:3055\u201365.","journal-title":"Genes Dev"},{"key":"1650_CR38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semcancer.2019.05.018","volume":"64","author":"MA Anwar","year":"2020","unstructured":"Anwar MA, El-Baba C, Elnaggar MH, Elkholy YO, Mottawea M, Johar D, et al. Novel therapeutic strategies for spinal osteosarcomas. Semin Cancer Biol. 2020;64:83\u201392.","journal-title":"Semin Cancer Biol"},{"key":"1650_CR39","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.20892\/j.issn.2095-3941.2022.0279","volume":"19","author":"H Mu","year":"2022","unstructured":"Mu H, Zuo D, Chen J, Liu Z, Wang Z, Yang L, et al. Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis. Cancer Biol Med. 2022;19:1397\u2013409.","journal-title":"Cancer Biol Med"},{"key":"1650_CR40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14:722\u201335.","journal-title":"Nat Rev Cancer"},{"key":"1650_CR41","doi-asserted-by":"crossref","unstructured":"Wei X, Feng J, Chen L, Zhang C, Liu Y, Zhang Y, et al. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Lett. 2024;611:217194.","DOI":"10.1016\/j.canlet.2024.217194"},{"key":"1650_CR42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385190","volume":"15","author":"J Korholz","year":"2024","unstructured":"Korholz J, Chen LS, Strauss T, Schuetz C, Dalpke AH. One gene to rule them all - clinical perspectives of a potent suppressor of cytokine signaling - SOCS1. Front Immunol. 2024;15:1385190.","journal-title":"Front Immunol"},{"key":"1650_CR43","first-page":"29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29\u201335.","journal-title":"Nat Genet"},{"key":"1650_CR44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cyto.2016.01.005","volume":"82","author":"C Beaurivage","year":"2016","unstructured":"Beaurivage C, Champagne A, Tobelaim WS, Pomerleau V, Menendez A, Saucier C. SOCS1 in cancer: an oncogene and a tumor suppressor. Cytokine. 2016;82:87\u201394.","journal-title":"Cytokine"},{"key":"1650_CR45","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.7150\/thno.49819","volume":"11","author":"L Lin","year":"2021","unstructured":"Lin L, Chen S, Wang H, Gao B, Kallakury B, Bhuvaneshwar K, et al. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma. Theranostics. 2021;11:4232\u201350.","journal-title":"Theranostics"},{"key":"1650_CR46","first-page":"1219","volume":"44","author":"HL Gong","year":"2019","unstructured":"Gong HL, Tao Y, Mao XZ, Song DY, You D, Ni JD. MicroRNA-29a suppresses the invasion and migration of osteosarcoma cells by regulating the SOCS1\/NF-kappaB signaling pathway through negatively targeting DNMT3B. Int J Mol Med. 2019;44:1219\u201332.","journal-title":"Int J Mol Med"},{"key":"1650_CR47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3389\/fonc.2020.01397","volume":"10","author":"D Chen","year":"2020","unstructured":"Chen D, Bao C, Zhao F, Yu H, Zhong G, Xu L, et al. Exploring specific miRNA-mRNA axes with relationship to taxanes-resistance in breast cancer. Front Oncol. 2020;10:1397.","journal-title":"Front Oncol"},{"key":"1650_CR48","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102317","volume":"52","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52:102317.","journal-title":"Redox Biol"},{"key":"1650_CR49","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1158\/0008-5472.CAN-06-2575","volume":"67","author":"K Zitzmann","year":"2007","unstructured":"Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, Meinecke J, et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 2007;67:5025\u201332.","journal-title":"Cancer Res"},{"key":"1650_CR50","volume":"62","author":"C Yang","year":"2023","unstructured":"Yang C, Li Y, Yang Y, Ni Q, Zhang Z, Chai Y, et al. Synthetic high-density lipoprotein-based nanomedicine to silence SOCS1 in tumor microenvironment and trigger antitumor immunity against glioma. Angew Chem Int Ed Engl. 2023;62:e202312603.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1650_CR51","volume":"10","author":"H Sun","year":"2024","unstructured":"Sun H, Li H, Guan Y, Yuan Y, Xu C, Fu D, et al. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Sci Adv. 2024;10:eadj8650.","journal-title":"Sci Adv"},{"key":"1650_CR52","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41418-023-01228-8","volume":"30","author":"M Mu","year":"2023","unstructured":"Mu M, Zhang Q, Li J, Zhao C, Li X, Chen Z, et al. USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A. Cell Death Differ. 2023;30:2393\u2013407.","journal-title":"Cell Death Differ"},{"key":"1650_CR53","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1670","volume":"14","author":"RS Perkins","year":"2024","unstructured":"Perkins RS, Murray G, Suthon S, Davis L, Perkins NB 3rd, Fletcher L, et al. WNT5B drives osteosarcoma stemness, chemoresistance and metastasis. Clin Transl Med. 2024;14:e1670.","journal-title":"Clin Transl Med"},{"key":"1650_CR54","volume":"24","author":"L Lou","year":"2024","unstructured":"Lou L, Deng T, Yuan Q, Wang L, Wang Z, Li X. Targeted silencing of SOCS1 by DNMT1 promotes stemness of human liver cancer stem-like cells. Cancer Cell Int. 2024;24:206.","journal-title":"Cancer Cell Int"},{"key":"1650_CR55","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau NPD, Laktyushin A, Lucet IS, Murphy JM, Yao S, Whitlock E, et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat Commun. 2018;9:1558.","journal-title":"Nat Commun"},{"key":"1650_CR56","volume":"71","author":"M Miao","year":"2024","unstructured":"Miao M, Pan M, Chen X, Shen J, Zhang L, Feng X, et al. IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. Redox Biol. 2024;71:103100.","journal-title":"Redox Biol"},{"key":"1650_CR57","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.16.4.1722","volume":"16","author":"MP Wymann","year":"1996","unstructured":"Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol. 1996;16:1722\u201333.","journal-title":"Mol Cell Biol"},{"key":"1650_CR58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1097-2765(05)00089-4","volume":"6","author":"EH Walker","year":"2000","unstructured":"Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6:909\u201319.","journal-title":"Mol Cell"},{"key":"1650_CR59","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/j.1460-2075.1996.tb00911.x","volume":"15","author":"GJ Brunn","year":"1996","unstructured":"Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256\u201367.","journal-title":"EMBO J"},{"key":"1650_CR60","first-page":"4375","volume":"58","author":"JN Sarkaria","year":"1998","unstructured":"Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998;58:4375\u201382.","journal-title":"Cancer Res"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01650-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:22:57Z","timestamp":1767424977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01650-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01650-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}